These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 9716243)
1. Propentofylline in the treatment of Alzheimer's disease and vascular dementia: a review of phase III trials. Rother M; Erkinjuntti T; Roessner M; Kittner B; Marcusson J; Karlsson I Dement Geriatr Cogn Disord; 1998 Jul; 9 Suppl 1():36-43. PubMed ID: 9716243 [TBL] [Abstract][Full Text] [Related]
2. Propentofylline in the treatment of vascular dementia and Alzheimer-type dementia: overview of phase I and phase II clinical trials. Mielke R; Möller HJ; Erkinjuntti T; Rosenkranz B; Rother M; Kittner B Alzheimer Dis Assoc Disord; 1998; 12 Suppl 2():S29-35. PubMed ID: 9769027 [TBL] [Abstract][Full Text] [Related]
3. A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. The European Propentofylline Study Group. Marcusson J; Rother M; Kittner B; Rössner M; Smith RJ; Babic T; Folnegovic-Smalc V; Möller HJ; Labs KH Dement Geriatr Cogn Disord; 1997; 8(5):320-8. PubMed ID: 9298634 [TBL] [Abstract][Full Text] [Related]
4. Clinical trials in dementia with propentofylline. Kittner B; Rössner M; Rother M Ann N Y Acad Sci; 1997 Sep; 826():307-16. PubMed ID: 9329701 [TBL] [Abstract][Full Text] [Related]
5. Clinical trials of propentofylline in vascular dementia. European/Canadian Propentofylline Study Group. Kittner B Alzheimer Dis Assoc Disord; 1999; 13 Suppl 3():S166-71. PubMed ID: 10609697 [TBL] [Abstract][Full Text] [Related]
6. Economic impact of introducing propentofylline for the treatment of dementia in Sweden. Wimo A; Witthaus E; Rother M; Winblad B Clin Ther; 1998; 20(3):552-66; discussion 550-1. PubMed ID: 9663370 [TBL] [Abstract][Full Text] [Related]
7. Propentofylline for dementia. Frampton M; Harvey RJ; Kirchner V Cochrane Database Syst Rev; 2003; (2):CD002853. PubMed ID: 12804440 [TBL] [Abstract][Full Text] [Related]
8. Glial modulating and neurotrophic properties of propentofylline and its application to Alzheimer's disease and vascular dementia. Ringheim GE Ann N Y Acad Sci; 2000 Apr; 903():529-34. PubMed ID: 10818548 [No Abstract] [Full Text] [Related]
9. Investigating the natural course and treatment of vascular dementia and Alzheimer's disease. Parallel study populations in two randomized, placebo-controlled trials. Kittner B; De Deyn PP; Erkinjuntti T Ann N Y Acad Sci; 2000 Apr; 903():535-41. PubMed ID: 10818549 [No Abstract] [Full Text] [Related]
10. [New pharmacologic aspects in the neurologic profile of propentofylline (Karsivan ad us. vet.)]. Kapl D; Rudolphi KA Tierarztl Prax Ausg K Kleintiere Heimtiere; 1998 Sep; 26(5):317-21. PubMed ID: 9931990 [TBL] [Abstract][Full Text] [Related]
12. HWA 285 (propentofylline)--a new compound for the treatment of both vascular dementia and dementia of the Alzheimer type. Rother M; Kittner B; Rudolphi K; Rössner M; Labs KH Ann N Y Acad Sci; 1996 Jan; 777():404-9. PubMed ID: 8624121 [TBL] [Abstract][Full Text] [Related]
13. Propentofylline treatment for Alzheimer disease and vascular dementia: an economic evaluation based on functional abilities. Bachynsky J; McCracken P; Lier D; Alloul K; Jacobs P Alzheimer Dis Assoc Disord; 2000; 14(2):102-11. PubMed ID: 10850749 [TBL] [Abstract][Full Text] [Related]
14. Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials. Passmore AP; Bayer AJ; Steinhagen-Thiessen E J Neurol Sci; 2005 Mar; 229-230():141-6. PubMed ID: 15760632 [TBL] [Abstract][Full Text] [Related]
15. Study protocol for a phase III randomised controlled trial of Sailuotong (SLT) for vascular dementia and Alzheimer's disease with cerebrovascular disease. Karamacoska D; Chan DKY; Leung I; Liu JX; Brodaty H; Fahey PP; Bensoussan A; Chang DH PLoS One; 2023; 18(3):e0265285. PubMed ID: 36920949 [TBL] [Abstract][Full Text] [Related]
16. Cerebrolysin improves symptoms and delays progression in patients with Alzheimer's disease and vascular dementia. Allegri RF; Guekht A Drugs Today (Barc); 2012 Apr; 48 Suppl A():25-41. PubMed ID: 22514793 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic strategies based on immunological hypotheses of Alzheimer's disease. Möller HJ J Neural Transm Suppl; 1998; 54():175-86. PubMed ID: 9850926 [TBL] [Abstract][Full Text] [Related]